文献速递主动脉疾病

意大利Nexus主动脉弓腔内修复注册研究结果

Results from the Italian Nexus aRCH endovascular repair registry for endovascular aortic arch repair.
PubMed 文献 · J Vasc Surg · 2025-06-13

该多中心回顾性研究基于意大利INARCHER注册数据,评估Nexus与Nexus Duo支架系统行主动脉弓腔内修复的安全性和疗效。共纳入31例患者,技术成功率97%,围术期死亡率6.5%,主要不良事件率22.6%。作者认为该支架系统似乎是治疗主动脉弓夹层和动脉瘤的安全选择,但神经并发症不可忽视。

要点

  • Nexus/Nexus Duo支架系统行主动脉弓腔内修复技术成功率97%,围术期死亡率6.5%。
  • 主要卒中发生率6.5%,主要不良事件率22.6%。
  • 30天以后无主动脉相关死亡,免于相关再干预率97%(95%CI 91%-100%)。

核心结论

  • Nexus与Nexus Duo支架系统似乎是治疗主动脉弓夹层和动脉瘤的安全选择,并发症率与现有文献中此类高复杂度病例一致。
  • 主动脉弓腔内修复仍是具有挑战性的手术,神经并发症不可忽视,需要持续改进以改善患者预后。

研究设计与样本

  • 多中心、回顾性研究,采用前瞻性收集的数据,作为意大利Nexus主动脉弓腔内修复注册研究(INARCHER)的一部分,于2019年至2024年间开展。
  • 共纳入31例在参与中心接受Nexus或Nexus Duo支架系统行主动脉弓腔内修复的患者,涵盖主动脉弓动脉瘤和夹层。
  • Nexus平台包括即用型双模块单分支支架和定制型双分支装置。

主要发现

  • 平均年龄73.4±7.32岁,男性占77.4%。
  • 13例为退行性动脉瘤,3例为既往外科修复后假性动脉瘤,2例为穿透性主动脉溃疡,13例为主动脉夹层(亚急性1例,慢性12例)。
  • 既往升主动脉置换15例(48.4%),急诊治疗7例(22.6%)。
  • 技术成功率达97%,因1例IA型内漏未达到;围术期死亡率6.5%(与大面积肺栓塞和心脏骤停相关),主要卒中发生率6.5%,主要不良事件率22.6%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study is to evaluate the safety, efficacy, and clinical outcomes of endovascular aortic arch repair using the Nexus and Nexus Duo endograft systems. METHODS: A multicenter, retrospective study with prospectively collected data was conducted as part of the Italian Nexus Aortic aRCH Endovascular Repair Registry (INARCHER) between 2019 and 2024. Nexus platforms include an off-the-shelf bimodular single branch endograft and a custom-made double-branch device. Patients who underwent endovascular aortic arch repair with the Nexus and Nexus Duo endograft systems at participating centers were included. The study addressed both aortic arch aneurysm and dissection. Data collection included baseline patient characteristics, procedural details, and follow-up results. The primary endpoints were early (30 days) major adverse events, major stroke, and mortality. Secondary endpoints included the need for device-related reintervention and the device-related endoleak. RESULTS: We collected 31 cases from 11 centers. The mean age was 73.4 ± 7.32 years, and 77.4% were male. Thirteen patients had a degenerative aneurysm, three had a pseudoaneurysm after prior surgical repair, two had penetrating aortic ulcers, and 13 had an aortic dissection (subacute, n = 1; chronic, n = 12). Prior ascending aorta replacement was present in 15 cases (48.4%). Seven patients (22.6%) received urgent treatment. Twenty-five cases were treated with complete supra-aortic trunks debranching and Nexus, six cases with left subclavian artery-left common carotid artery debranching and Nexus Duo. The mean operative time was 230 ± 73 minutes. Technical success was achieved in 97% of procedures owing to one case of type IA endoleak. Perioperative mortality was 6.5%, related to a massive pulmonary embolism and a cardiac arrest. Major strokes occurred in 6.5%. The major adverse event rate was 22.6%. The mean follow-up period was 29.7 ± 24.9 months. Beyond 30 days, there was no aortic-related mortality, and freedom from related reintervention was 97% (95% confidence interval, 91%-100%). CONCLUSIONS: The use of the Nexus and Nexus Duo endograft systems appears to be a safe option for the treatment of aortic arch dissection and aneurysm, with complication rates consistent with existing literature for such high-complexity cases. Endovascular aortic arch repair remains a challenging procedure with non-negligible neurologic complication, requiring ongoing improvements to enhance patient outcomes.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Antonello M, Spertino A, Gatta E, et al. Results from the Italian Nexus aRCH endovascular repair registry for endovascular aortic arch repair. J Vasc Surg. 2025. PMID: 40517849. doi:10.1016/j.jvs.2025.05.201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。